Is IL-1 the answer to safer CAR-T?

The novel immunotherapy that is CAR-T seems to be the hot topic of the oncology market and has held it’s place there for quite some time. However, there are major safety issues when it comes to this immuno-oncology therapy. This article gives some insights into how scientists are trying to understand and overcome the safety issues related to CAR-T and how to move passed them. Link to article below. 

On 30-05-2018 0 1597

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.


Make an appointment and we’ll contact you.